Sabrina McCrear

Stephen Greene, MD, discusses the future and practical implications of optimizing quadruple foundational therapies for patients with heart failure.

Here are 5 reasons why bariatric surgery may be better for weight loss than GLP-1 receptor agonists

Clinician's role in breast cancer care and access with reproductive and urinary oncologist Lakshminarayanan Nandagopal, MD

Advancements in breast cancer care and treatments with reproductive and urinary oncologist Lakshminarayanan Nandagopal, MD.

FDA approved the monotherapy for estrogen receptor (ER)–positive and HER2-negative metastatic breast cancer.

Patients with myasthenia gravis had more COVID-19–related anxieties due to their diagnosis and immunosuppressive therapies.

Leucovorin is under FDA review to expand treatment for children with cerebral folate deficiency, which has been assciated with autism.

Medicare beneficiaries with near low income experience more affordability issues than beneficiaries with low income due to Medicare savings programs eligibility.

On this episode of Managed Care Cast, experts discuss the practical implications of bias in electronic health care records.

Tirzepatide appears more cost-effective than semaglutide for obesity and knee osteoarthritis, though long-term data and patient-centered outcomes remain key.

The American Heart Association (AHA) launched a news initiative to address challenges with in-hospital care for patients with different types of heart failure.

The Oncotype DX 21-gene recurrence score helps guide adjuvant therapy in women with early-stage breast cancer and low genomic risk.

Ruxolitinib cream received an expanded approval to treat patients as young as 2 years old with non-immunocompromised mild to severe atopic dermatitis.

Tirzepatide’s cost-effectiveness provides key evidence for policy makers implementing clinical coverage decisions.

Bariatric surgery is more efficient at increasing weight loss and more cost-effective than GLP-1 RAs.

Elena Losina, PhD, codirector of the Orthopedics and Arthritis Center for Outcomes Research at Brigham and Women’s Hospital, discusses the cost-effectiveness of varying weight loss interventions.

The transthyretin cardiac amyloidosis (ATTR-CA) variant is more prevalent in Black individuals, increasing the need for more research to assess hereditary links and early prevention awareness.

Researchers in Denmark observed a significant drop-off in anti-obesity drug usage after 1 year in first-time users.

GLP-1 RA tirzepatide may be more cost-effective for patients with obesity and knee osteoarthritis than semaglutide.

Survivorship care and patient tools like the breast cancer index help patients and doctors curate an individualized survivorship plan for each patient.

US foreign aid budget cuts and freezes may potentially increase those affected by tuberculosis in USAID-dependent countries, resulting in millions of lives lost.

COVID-19 worsened disparities in cervical cancer screening and HPV vaccine awareness, impacting minority groups with limited access to preventive care.

Participating hospitals in the Prime Vendor Program and the 340B program spent nearly $37.3 billion more on drugs from 2010 to 2021.

Olivo Adriana, NP, highlights the importance of survivorship care and how providers are utilizing available tools to the best of their ability.

The Breast Cancer Index and artificial intelligence–assisted mammograms are tools that can help mitigate symptoms and reassure patient insecurities of women with breast cancer post-treatment.

Bariatric surgery reduces the likelihood of obesity-related comorbidities compared with nonsurgical weight loss interventions.

Social determinants of health were associated with a younger age of first hospitalization for heart failure in Black and Hispanic patients when compared with Asian and White patients.

A new study evaluated real-world data on the efficacy of GLP-1s in patients with obesity and heart failure with preserved ejection fraction (HFpEF), confirming findings from prior research.

Researchers call for further studies on GLP-1 initiation after bariatric surgery to better understand its real-world impact.

In an observational extension of the myPACE clinical trial, researchers found that a personalized accelerated pacing in patients with heart failure with preserved ejection fraction (HFpEF) and a preexisting physiological pacer saw a slower trend in adverse cardiac events and overall improved health status.